Monte Rosa Therapeutics, Inc.
$19.81
▼
-0.47%
2026-04-21 07:07:00
www.monterosatx.com
NMS: GLUE
Explore Monte Rosa Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.58 B
Current Price
$19.81
52W High / Low
$25.77 / $3.51
Stock P/E
—
Book Value
$3.56
Dividend Yield
—
ROCE
-14.1%
ROE
-16.94%
Face Value
—
EPS
$-0.46
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
150
Beta
1.64
Debt / Equity
16.82
Current Ratio
6.12
Quick Ratio
6.12
Forward P/E
-10.46
Price / Sales
11.31
Enterprise Value
$1.06 B
EV / EBITDA
-23.13
EV / Revenue
8.58
Rating
None
Target Price
$32.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Immunic, Inc. | $0.95 | — | $124.59 M | — | 1572.16% | -16.53% | $1.51 / $0.51 | $-0.06 |
| 2. | Acrivon Therapeutics, Inc. | $1.86 | — | $68.97 M | — | -73.75% | -53.86% | $3.56 / $1.05 | $3.56 |
| 3. | Evogene Ltd. | $0.8 | — | $7.92 M | — | -84.53% | -1.01% | $2.42 / $0.72 | $-0.01 |
| 4. | Zevra Therapeutics, Inc. | $10.78 | 7.23 | $601.51 M | — | -1.72% | 85.66% | $13.16 / $6.85 | $2.72 |
| 5. | Palatin Technologies, Inc. | $22.07 | — | $39.22 M | — | 478.76% | -3.79% | $31 / $2 | $6.53 |
| 6. | GT Biopharma, Inc. | $0.37 | — | $11.72 M | — | -214.65% | -13.77% | $3.85 / $0.35 | $0.23 |
| 7. | Day One Biopharmaceuticals, Inc. | $21.48 | — | $2.22 B | — | -28.56% | -22.74% | $21.49 / $5.63 | $4.28 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 2.78 M | 12.77 M | 23.19 M | 84.93 M | 60.65 M |
| Operating Profit | -49.72 M | -32.98 M | -15.55 M | 44.04 M | 13 M |
| Net Profit | -46.13 M | -27.08 M | -12.29 M | 46.88 M | 13.44 M |
| EPS in Rs | -0.58 | -0.34 | -0.15 | 0.59 | 0.17 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 123.67 M | 75.62 M | 0 M | 0 M |
| Operating Profit | -54.21 M | -81.11 M | -143.31 M | -112.38 M |
| Net Profit | -38.63 M | -72.7 M | -135.35 M | -108.5 M |
| EPS in Rs | -0.48 | -0.91 | -1.69 | -1.36 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 448.66 M | 438.73 M | 303.75 M | 342.39 M |
| Total Liabilities | 215.6 M | 215.8 M | 124.5 M | 70.98 M |
| Equity | 233.06 M | 222.94 M | 179.25 M | 271.41 M |
| Current Assets | 393.19 M | 377.44 M | 236.21 M | 275.89 M |
| Current Liabilities | 64.21 M | 156.95 M | 46.59 M | 25.57 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -22.8 M | 42 M | -43.8 M | -92.47 M |
| Investing CF | -101.83 M | -44.45 M | 88.8 M | -219.22 M |
| Financing CF | 30.35 M | 98.89 M | 27.49 M | 20.47 M |
| Free CF | -27.5 M | 38.01 M | -62.84 M | -105.38 M |
| Capex | -4.7 M | -3.99 M | -19.04 M | -12.91 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 46.29% | -24.75% | — | — |
| Profit Margin % | -96.14% | — | — | — |
| Operating Margin % | -107.26% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -96.52% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.